Search

A recent study conducted by Paratek Pharmaceuticals Inc. has found that omadacycline, an antibiotic, is effective against ciprofloxacin-resistant Bacillus anthracis, the bacteria that causes anthrax. The study assessed the in vitro activity and in vivo efficacy of omadacycline against clinical isolates of B. anthracis, including a ciprofloxacin-resistant strain. The results showed that omadacycline demonstrated both in vitro activity and in vivo efficacy against B. anthracis, suggesting that it may be a potential treatment option for inhalation anthrax caused by antibiotic-resistant strains. As antibiotic resistance rates continue to rise, omadacycline could provide an alternative treatment option for anthrax. [Extracted from the article]

A recent report from the University of Leeds provides new data on anthrax vaccines. The research focuses on the protein called protective antigen (PA) produced by Bacillus anthracis, which is a key component of anthrax vaccines. The study uses mathematical modeling and statistical techniques to quantify PA production and decay, and proposes a mathematical model that explains the dynamics of the data. The findings contribute to the development of more realistic models of anthrax infection and the understanding of toxin dynamics, immune response, and anti-toxin treatments. [Extracted from the article]

This article discusses the research being conducted by Tod Merkel, PhD, on the interaction between humans and three bacterial pathogens: Bordetella pertussis, Bacillus anthracis, and Staphylococcus aureus. The goal of the research is to gain a better understanding of these pathogens and develop new vaccines and treatments for the diseases they cause. The article also mentions the use of animal models to study the immune response and evaluate the efficacy of vaccines. The research conducted by Merkel's laboratory helps identify potential problems with these products and provides advice to developers and manufacturers. [Extracted from the article]

A recent study conducted by researchers at the University of California has examined the treatment of anthrax meningitis, a severe central nervous system infection. The researchers reviewed medical literature and regulatory documents to determine the effectiveness of various antimicrobial drugs in treating this condition. They found that several drugs, including ciprofloxacin and penicillin G, were likely to achieve effective antimicrobial activity in the cerebrospinal fluid. The study also suggested that certain drugs, such as clindamycin and linezolid, could be used in combination therapy to decrease toxin production. Prompt and appropriate antimicrobial therapy may help reduce the high morbidity and mortality associated with anthrax meningitis. [Extracted from the article]

A recent study conducted by researchers from the Institut de Recherche Biomedicale des Armees in France has shed new light on the early stages of inhalational anthrax infection. The study focused on the role of edema factor (EF), one of the enzymatic proteins involved in anthrax toxins. The researchers found that EF can enter cells independently of the protective antigen (PA), but PA is still required for EF to induce an increase in intracellular cAMP levels. The study suggests that PA and EF may functionally associate during intracellular trafficking. This research provides valuable insights into the mechanisms of anthrax infection. [Extracted from the article]

A recent report from Changchun University of Science and Technology in China describes the development of a fluorescence sensor for the visualized detection of an anthrax biomarker called 2,6-pyridine dicarboxylic acid (DPA). The sensor, based on lanthanide-metal-organic frameworks (MOFs), demonstrated sensitivity, stability, and anti-interference ability for DPA detection. It also showed a color change from red to blue with increasing DPA concentration under UV light. The sensor was successfully applied to fetal calf serum and tap water, and it was immobilized onto a polyvinyl alcohol membrane for portable monitoring of DPA. This research has been peer-reviewed and published in Inorganic Chemistry Frontiers. [Extracted from the article]

Researchers from Mashhad University of Medical Sciences in Iran have reported a case of cutaneous anthrax in a one-year-old infant. Anthrax is a rare bacterial infection that is usually work-related and more commonly affects adults. The infant developed a swollen lesion with a dark crust on the corner of their lip after coming into contact with contaminated broth. Although the culture result was negative, Bacillus anthracis was seen in a direct smear of the wound. The researchers emphasize the importance of timely antibiotic treatment to reduce mortality and prevent the spread of the bacteria in the blood. [Extracted from the article]

Keywords: Anthrax; Antibodies; Bacillaceae Infections; Blood Proteins; Center for Drug Evaluation and Research; Drugs and Therapies; Genetics; Gram-Positive Bacterial Infections; Health and Medicine; Immunoglobulins; Immunology; Proteins; Therapeutics; Therapy; U.S. Food and Drug Administration EN Anthrax Antibodies Bacillaceae Infections Blood Proteins Center for Drug Evaluation and Research Drugs and Therapies Genetics Gram-Positive Bacterial Infections Health and Medicine Immunoglobulins Immunology Proteins Therapeutics Therapy U.S. Food and Drug Administration 3618 3618 1 09/11/23 20230917 NES 230917 2023 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- A new study on anthrax is now available. For this reason, anti-PA antibodies have been developed as therapeutics for prophylaxis and treatment of human anthrax infection. [Extracted from the article]

Keywords: Adverse Drug Reactions; Aminotransferase; Anthrax; Anthrax Vaccines; Antibodies; Bacillaceae Infections; Bacterial Vaccines; Biological Products; Blood Proteins; Clinical Research; Clinical Trials and Studies; Communicable Disease Control; Digestive System Diseases and Conditions; Drugs and Therapies; Environment and Public Health; Enzymes and Coenzymes; Gastroenterology; Gram-Positive Bacterial Infections; Health and Medicine; Hepatitis; Immunization; Immunization and Public Health; Immunization and Public Health - Anthrax Vaccines; Immunoglobulins; Immunology; Immunoproteins; Infectious Diseases and Conditions; Liver Diseases and Conditions; Neutralizing Antibodies; Placebos; Proteins; Public Health; Public Health Practice; Vaccination; Vaccines EN Adverse Drug Reactions Aminotransferase Anthrax Anthrax Vaccines Antibodies Bacillaceae Infections Bacterial Vaccines Biological Products Blood Proteins Clinical Research Clinical Trials and Studies Communicable Disease Control Digestive System Diseases and Conditions Drugs and Therapies Environment and Public Health Enzymes and Coenzymes Gastroenterology Gram-Positive Bacterial Infections Health and Medicine Hepatitis Immunization Immunization and Public Health Immunization and Public Health - Anthrax Vaccines Immunoglobulins Immunology Immunoproteins Infectious Diseases and Conditions Liver Diseases and Conditions Neutralizing Antibodies Placebos Proteins Public Health Public Health Practice Vaccination Vaccines 365 365 1 09/04/23 20230908 NES 230908 2023 SEP 4 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Staff editors report on the newly launched clinical trial, NCT05997264, which has the following summary description: "This randomized, phase 2, double-blinded, multicenter study is designed to assess the safety and immune response kinetics of AV7909 administered on 2 primary series vaccination schedules followed by 6- and 12-month boosters.". [Extracted from the article]

Breathing anthrax spores can cause inhalation anthrax. Keywords: Anthrax; Bacillaceae Infections; Bioengineering; Biological Agents; Biologics; Biotechnology; Bioterrorism; Business; Center for Biologics Evaluation and Research; FDA; Genetic Engineering; Genetically-Engineered Proteins; Government Agencies Offices and Entities; Gram-Positive Bacterial Infections; Risk and Prevention; Terrorism; U.S. Food and Drug Administration EN Anthrax Bacillaceae Infections Bioengineering Biological Agents Biologics Biotechnology Bioterrorism Business Center for Biologics Evaluation and Research FDA Genetic Engineering Genetically-Engineered Proteins Government Agencies Offices and Entities Gram-Positive Bacterial Infections Risk and Prevention Terrorism U.S. Food and Drug Administration 766 766 1 08/07/23 20230811 NES 230811 2023 AUG 13 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Anthrax is a serious infectious disease caused by spores of the bacterium, Bacillus anthracis (B. anthracis). The death rates from anthrax infection without treatment vary, depending on the type of exposure, and are approximately 20% for cutaneous anthrax, over 50% for gastrointestinal anthrax; and inhalation anthrax is almost always fatal. [Extracted from the article]

Keywords for this news article include: Paris, France, Europe, Angiology, Anthrax, Bacillaceae Infections, Bubonic Plague, Enterobacteriaceae Infections, Gram-Negative Bacteria, Gram-Positive Bacterial Infections, Health and Medicine, Hemorrhage, Infectious Diseases and Conditions, Intravascular, Plague, Yersinia Infections, University of Paris. Paris, France, Europe, Angiology, Anthrax, Bacillaceae Infections, Bubonic Plague, Enterobacteriaceae Infections, Gram-Negative Bacteria, Gram-Positive Bacterial Infections, Health and Medicine, Hemorrhage, Infectious Diseases and Conditions, Intravascular, Plague, Yersinia Infections Keywords: Paris; France; Europe; Angiology; Anthrax; Bacillaceae Infections; Bubonic Plague; Enterobacteriaceae Infections; Gram-Negative Bacteria; Gram-Positive Bacterial Infections; Health and Medicine; Hemorrhage; Infectious Diseases and Conditions; Intravascular; Plague; Yersinia Infections EN Paris France Europe Angiology Anthrax Bacillaceae Infections Bubonic Plague Enterobacteriaceae Infections Gram-Negative Bacteria Gram-Positive Bacterial Infections Health and Medicine Hemorrhage Infectious Diseases and Conditions Intravascular Plague Yersinia Infections 6825 6825 1 06/12/23 20230616 NES 230616 2023 JUN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- A new study on Infectious Diseases and Conditions - Bubonic Plague is now available. [Extracted from the article]

Keywords: Algorithms; Anthrax; Bacillaceae Infections; Biological Agents; Bioterrorism; Biowarfare; Gram-Positive Bacterial Infections; Health and Medicine; Psychosocial; Terrorism EN Algorithms Anthrax Bacillaceae Infections Biological Agents Bioterrorism Biowarfare Gram-Positive Bacterial Infections Health and Medicine Psychosocial Terrorism 5253 5253 1 04/03/23 20230407 NES 230407 2023 APR 7 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on anthrax. According to the news editors, the research concluded: "For triage algorithms for most bioterrorism events, it is necessary to determine the time and place of the attack as soon as possible, control the number of exposed and potentially exposed people, prevent infection and determine the type of biological agents used. [Extracted from the article]